57m
Hosted on MSNFour regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide platform trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results